192 related articles for article (PubMed ID: 37773632)
1. Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma.
Marino-Enriquez A; Novotny JP; Gulhan DC; Klooster I; Tran AV; Kasbo M; Lundberg MZ; Ou WB; Tao DL; Pilco-Janeta DF; Mao VY; Zenke FT; Leeper BA; Gokhale PC; Cowley GS; Baker LH; Ballman KV; Root DE; Albers J; Park PJ; George S; Fletcher JA
Clin Cancer Res; 2023 Dec; 29(24):5128-5139. PubMed ID: 37773632
[TBL] [Abstract][Full Text] [Related]
2. PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.
Babichev Y; Kabaroff L; Datti A; Uehling D; Isaac M; Al-Awar R; Prakesch M; Sun RX; Boutros PC; Venier R; Dickson BC; Gladdy RA
J Transl Med; 2016 Mar; 14():67. PubMed ID: 26952093
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of aberrantly overexpressed Polo-like kinase 4 is a potential effective treatment for DNA damage repair-deficient uterine leiomyosarcoma.
Lee HHY; Chow KL; Wong HS; Chong TY; Wong AST; Cheng GHW; Ko JMK; Siu HC; Yeung MCF; Huen MSY; Tse KY; Bray MR; Mak TW; Leung SY; Ip PPC
Clin Cancer Res; 2024 Jun; ():. PubMed ID: 38848043
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression.
Hemming ML; Bhola P; Loycano MA; Anderson JA; Taddei ML; Doyle LA; Lavrova E; Andersen JL; Klega KS; Benson MR; Crompton BD; Raut CP; George S; Letai A; Demetri GD; Sicinska E
Clin Cancer Res; 2022 Jun; 28(11):2397-2408. PubMed ID: 35325095
[TBL] [Abstract][Full Text] [Related]
5. Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models.
Revia S; Neumann F; Jabs J; Orio F; Sirrenberg C; Zimmermann A; Amendt C; Albers J
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791158
[TBL] [Abstract][Full Text] [Related]
6. Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma.
Liu W; Tong H; Zhang C; Zhuang R; Guo H; Lv C; Yang H; Lin Q; Guo X; Wang Z; Wang Y; Shen F; Wang S; Dai C; Wang G; Liu J; Lu W; Zhang Y; Zhou Y
BMC Cancer; 2020 Oct; 20(1):1035. PubMed ID: 33115433
[TBL] [Abstract][Full Text] [Related]
7. Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.
Schaefer IM; Lundberg MZ; Demicco EG; Przybyl J; Matusiak M; Chibon F; Ingram DR; Hornick JL; Wang WL; Bauer S; Baker LH; Lazar AJ; van de Rijn M; Mariño-Enríquez A; Fletcher JA
Cancer; 2021 Aug; 127(15):2666-2673. PubMed ID: 33788262
[TBL] [Abstract][Full Text] [Related]
8. Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers.
Patterson-Fortin J; Bose A; Tsai WC; Grochala C; Nguyen H; Zhou J; Parmar K; Lazaro JB; Liu J; McQueen K; Shapiro GI; Kozono D; D'Andrea AD
Cancer Res; 2022 Oct; 82(20):3815-3829. PubMed ID: 35972384
[TBL] [Abstract][Full Text] [Related]
9. Integrative genomic and transcriptomic analysis of leiomyosarcoma.
Chudasama P; Mughal SS; Sanders MA; Hübschmann D; Chung I; Deeg KI; Wong SH; Rabe S; Hlevnjak M; Zapatka M; Ernst A; Kleinheinz K; Schlesner M; Sieverling L; Klink B; Schröck E; Hoogenboezem RM; Kasper B; Heilig CE; Egerer G; Wolf S; von Kalle C; Eils R; Stenzinger A; Weichert W; Glimm H; Gröschel S; Kopp HG; Omlor G; Lehner B; Bauer S; Schimmack S; Ulrich A; Mechtersheimer G; Rippe K; Brors B; Hutter B; Renner M; Hohenberger P; Scholl C; Fröhling S
Nat Commun; 2018 Jan; 9(1):144. PubMed ID: 29321523
[TBL] [Abstract][Full Text] [Related]
10. Targeting TJP1 attenuates cell-cell aggregation and modulates chemosensitivity against doxorubicin in leiomyosarcoma.
Lee EY; Yu JY; Paek AR; Lee SH; Jang H; Cho SY; Kim JH; Kang HG; Yun T; Oh SE; Park SY; You HJ
J Mol Med (Berl); 2020 May; 98(5):761-773. PubMed ID: 32318747
[TBL] [Abstract][Full Text] [Related]
11. Targeted exome sequencing profiles genetic alterations in leiomyosarcoma.
Agaram NP; Zhang L; LeLoarer F; Silk T; Sung YS; Scott SN; Kuk D; Qin LX; Berger MF; Antonescu CR; Singer S
Genes Chromosomes Cancer; 2016 Feb; 55(2):124-30. PubMed ID: 26541895
[TBL] [Abstract][Full Text] [Related]
12.
Seligson ND; Kautto EA; Passen EN; Stets C; Toland AE; Millis SZ; Meyer CF; Hays JL; Chen JL
Oncologist; 2019 Jul; 24(7):973-979. PubMed ID: 30541756
[TBL] [Abstract][Full Text] [Related]
13. Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates.
Lopez G; Braggio D; Zewdu A; Casadei L; Batte K; Bid HK; Koller D; Yu P; Iwenofu OH; Strohecker A; Choy E; Lev D; Pollock R
PLoS One; 2017; 12(11):e0188859. PubMed ID: 29186204
[TBL] [Abstract][Full Text] [Related]
14. Genetic evidence for the involvement of DNA ligase IV in the DNA-PK-dependent pathway of non-homologous end joining in mammalian cells.
Wang H; Zeng ZC; Perrault AR; Cheng X; Qin W; Iliakis G
Nucleic Acids Res; 2001 Apr; 29(8):1653-60. PubMed ID: 11292837
[TBL] [Abstract][Full Text] [Related]
15. Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.
Suehara Y; Kohsaka S; Hayashi T; Akaike K; Kurisaki-Arakawa A; Sato S; Kobayashi E; Mizuno S; Ueno T; Morii T; Okuma T; Kurihara T; Hasegawa N; Sano K; Sasa K; Okubo T; Kim Y; Mano H; Saito T
Clin Orthop Relat Res; 2021 Apr; 479(4):838-852. PubMed ID: 33196586
[TBL] [Abstract][Full Text] [Related]
16. Leiomyosarcomas: whole genome sequencing for a whole biology characterization.
Chibon F; Darbo E; Pérot G
Curr Opin Oncol; 2019 Jul; 31(4):317-321. PubMed ID: 31033567
[TBL] [Abstract][Full Text] [Related]
17. DNA-Dependent Protein Kinase Inhibitor Peposertib Potentiates the Cytotoxicity of Topoisomerase II Inhibitors in Synovial Sarcoma Models.
Revia S; Budzinska MA; Bogatyrova O; Neumann F; Zimmermann A; Amendt C; Albers J
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201616
[TBL] [Abstract][Full Text] [Related]
18. HPV51-associated Leiomyosarcoma: A Novel Class of TP53/RB1-Wildtype Tumor With Predilection for the Female Lower Reproductive Tract.
Williams EA; Montesion M; Lincoln V; Tse JY; Hiemenz MC; Mata DA; Shah BB; Shoroye A; Alexander BM; Werth AJ; Foley-Peres K; Milante RR; Ross JS; Ramkissoon SH; Williams KJ; Adhikari LJ; Zuna RE; LeBoit PE; Lin DI; Elvin JA
Am J Surg Pathol; 2022 Jun; 46(6):729-741. PubMed ID: 35034043
[TBL] [Abstract][Full Text] [Related]
19. Copper ions are novel therapeutic agents for uterine leiomyosarcoma.
Kakuda M; Matsuzaki S; Ueda Y; Shiomi M; Matsuzaki S; Kimura T; Fujita M; Egawa-Takata T; Kobayashi E; Serada S; Yoshino K; Naka T; Kimura T
Am J Obstet Gynecol; 2020 Jan; 222(1):64.e1-64.e16. PubMed ID: 31351063
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of NCC-LMS3-C1: a novel patient-derived cell line of leiomyosarcoma.
Yoshimatsu Y; Noguchi R; Osaki J; Sin Y; Tsuchiya R; Ono T; Akiyama T; Adachi Y; Tanzawa Y; Yoshida A; Kawai A; Kondo T
Hum Cell; 2024 Jan; 37(1):337-344. PubMed ID: 37907774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
